Antitumour and immune-adjuvant activities of protein-tyrosine kinase inhibitors.
Seliger
Barbara
B
Martin-Luther-Universitaet Halle-Wittenberg, Institute of Medical Immunology, 06112 Halle (Saale), Germany. Barbara.Seliger@medizin.uni-halle.de <Barbara.Seliger@medizin.uni-halle.de>
Massa
Chiara
C
Rini
Brian
B
Ko
Jennifer
J
Finke
Jim
J
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003713:Dendritic Cells / Q000187:drug effects; D006801:Humans; D007167:Immunotherapy; D051379:Mice; D009369:Neoplasms / Q000201:enzymology / Q000276:immunology / Q000628:therapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000276:immunology; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects / Q000276:immunology
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors